NASDAQ:NEPH Nephros Q2 2025 Earnings Report $3.68 +0.55 (+17.57%) Closing price 04:00 PM EasternExtended Trading$3.72 +0.04 (+1.09%) As of 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Nephros EPS ResultsActual EPS$0.02Consensus EPS -$0.03Beat/MissBeat by +$0.05One Year Ago EPSN/ANephros Revenue ResultsActual Revenue$4.40 millionExpected Revenue$3.60 millionBeat/MissBeat by +$799.00 thousandYoY Revenue GrowthN/ANephros Announcement DetailsQuarterQ2 2025Date8/7/2025TimeAfter Market ClosesConference Call DateThursday, August 7, 2025Conference Call Time4:30PM ETUpcoming EarningsNephros' Q2 2026 earnings is estimated for Thursday, August 6, 2026, based on past reporting schedules, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesConference Call AudioConference Call TranscriptPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Nephros Q2 2025 Earnings Call TranscriptProvided by QuartrAugust 7, 2025 ShareLink copied to clipboard.Key Takeaways Positive Sentiment: Strong Q2 performance with net revenue up 36% year-over-year to $4.4 M and third consecutive quarter of profitability with positive adjusted EBITDA. Positive Sentiment: Gross margin expanded to 63% in Q2 from 59% a year ago, driven by reduced shipping costs and favorable inventory reserve adjustments. Positive Sentiment: Net cash provided by operating activities reached $994 K in Q2 versus a $501 K outflow last year, and the company remains debt-free with $5.1 M in cash. Positive Sentiment: Active customer sites grew to over 1,600, with programmatic business up 40% over two years, fueled by the filter tracking app, installation program, and expanded sales team. Negative Sentiment: Operating expenses rose as R&D spending increased due to higher headcount and SG&A climbed 13% on elevated sales commissions and stock-based compensation. AI Generated. May Contain Errors.Conference Call Audio Live Call not available Earnings Conference CallNephros Q2 202500:00 / 00:00Speed:1x1.25x1.5x2xThere are 4 speakers on the call. Operator00:00:00Okay, and welcome to the Nephros, Inc. second quarter 2025 financial results conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your questions, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to Karen Smith in PTG Advisory. Please go ahead. Speaker 200:00:36Thank you, Megan. Good afternoon, everyone. This is Karen Smith with PTG Advisory. Thank you all for participating in Nephros's second quarter 2025 conference call. Before we begin, I would like to caution that comments made during this conference call by management will contain forward-looking statements regarding the operations and future results of Nephros. On call here to review Nephros's bilingual statistics and exchange commission, including without limitation, the company is formed from 12, be 10 to identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements. Speaker 200:01:13Factors that may affect the company's results include, but are not limited to, Nephros's ability to successfully, timely, and cost-effectively market and sell its products and service offerings, the rate of adoption of its products and services by hospitals and other healthcare providers, the success of its commercialization efforts, and the effect of existing and new regulatory requirements on Nephros's business and other economic and competitive factors. The contents of this conference call contain time-sensitive information. It is accurate only as of the date of the live call today, August 7, 2025. I'm going to undertake no obligation to revise or update any statements to reflect events or circumstances as to the date of this conference call, except as required by law. I would now like to turn the call over to Nephros's President and Chief Executive Officer, Robert Banks. Robert, please go ahead. Speaker 300:02:05Thank you, Karen. Good afternoon, everyone. I'm thrilled to be speaking with you today as we share our Q2 2025 results. We've grown our total 12-month revenue from $13.8 million to $16.7 million, added more than 400 new active customer sites over the past two years, and most importantly, have continued to prove our strategy works. Q2 was another high-achieving quarter. Net revenue reached $4.4 million, up 36% over Q2 last year, and marks the third consecutive quarter of profitability. These are not just financial milestones, they are clear signals of durable momentum and strong operational execution. When you zoom out to look at the first half of 2025, the growth becomes even more compelling. The first half of 2025 revenue hit $9.3 million, a 37% increase over the same period in 2024. Every region outperformed its first half targets. Speaker 300:03:16Overall, we delivered well above our internal targets, reinforcing both the resilience and scalability of our business. Much of this success is driven by our core programmatic business, which has now seen 40% compound growth over the past two years. In fact, programmatic sales reached all-time highs, confirming the efficacy of our recurring revenue model. We have also seen encouraging traction in other key areas: a thriving installation program, which has accelerated reorder rates and expanded our footprint, a record level of programmatic sales, even with lower emergency response volumes, the strategic expansion of our sales teams into non-healthcare verticals has begun to pay off, and growing customer adoption of our filter tracking app, which has improved visibility, compliance, and support, with thousands of filters now being tracked. This quarter's strong execution reflects the entire team's commitment, from sales and operations to product and customer success. Speaker 300:04:29We now serve over 1,500 active customer sites and are delighted that our Q2 brought in the highest retention rate of the past six quarters. Looking ahead, we are focused on three things: expanding into underserved verticals like dental, government, and municipal facilities, bringing new innovations to market like our S100 microfilter and 20-inch HydraGuard, which have unlocked opportunities across sterile processing, laboratories, and beyond, and lastly, executing with operational discipline while continuing to protect profitability. To everyone who has supported our journey so far, thank you. I am deeply proud of what we've built and even more excited about what's next. With that, I'll turn the call over to our CFO, Judy Krandel, for a more detailed look at our financials. Judy? Operator00:05:32Thanks, Robert. I will now provide a closer look at Nephros's financial performance in the second quarter and first half of 2025. We reported second quarter net revenue of $4.4 million, a 36% increase over the corresponding period in 2024, reflecting strong growth in our programmatic business and emergency response business. Active customer sites continued to grow and were over 1,600 as of June 30, 2025, slightly higher than at March 31, 2025. Gross margins in the quarter also increased to 63% compared with 59% in Q2 2024, an improvement of 4 percentage points. The improvement in gross margins in 2025 was primarily driven by a reduction in shipping costs and inventory reserves adjustment. Research and development expenses in the quarter were $311,000 compared to $254,000 for the same quarter in 2024. R&D expenses were higher this year due to an increase in headcount. Operator00:06:41Sales, general, and administrative expenses in the quarter were $2.2 million compared to $1.9 million for the corresponding period in 2024, an increase of 13% due to higher sales commissions resulting from our increased revenue, higher pool of employee bonuses, and higher stock compensation expense. We are very pleased to report positive net income for the quarter of $237,000 compared to a net loss of $289,000 in the same period last year. Adjusted EBITDA in the quarter was positive $355,000 compared to a loss of $133,000 during the same period in 2024. Net cash provided by operating activities was $994,000 in the second quarter of 2025 versus net cash used of $501,000 in the prior year period, an improvement of $1,495,000. Net cash provided in the second quarter reflects primarily our positive net income, a decrease in accounts receivable, and an increase in accrued expenses. Operator00:07:55Net cash used in the second quarter of 2024 reflects primarily the net loss in that period and an increase in accounts receivable and inventory. Moving on to the six months, the first half of this year, sales for the six months ending June 30, 2025 increased by 37% to $9.2 million from the prior year period, reflecting strong growth in our programmatic business and emergency response business. Gross margins improved to 64% in the first half of 2025 from 61% in the prior year period. The increase in gross margins was primarily driven by lower product costs resulting from a more favorable product mix and a reduction in inventory reserve adjustment. SG&A expenses increased by 9% in the first half of 2025 versus the prior year period due to higher sales commission expense, increased bonus accrual, and higher stock-based compensation expense. Operator00:09:00Net income increased to $795,000 in the first half of 2025 from a net loss of $458,000 in the prior year period. Adjusted EBITDA in the first half of the year was positive $1,022,000 compared to a loss of $228,000 during the same period in 2024. Our cash balance on June 30, 2025 was $5.1 million compared to $3.8 million as of December 31, 2024, and we continued to be debt-free. Please refer to today's press release for more details about the calculation of adjusted EBITDA and its reconciliation to GAAP net income or loss. Additional information about our results can be found in our filing in Form 10-Q, which we also filed this afternoon. I will now turn the call back to Robert for some closing remarks. Robert, please go ahead. Speaker 300:10:02Thank you, Judy. With an eye towards the future, we remain focused on scaling our successes and exploring new ways to drive value. The strides we've made operationally, commercially, and financially position Nephros to lead in a future where water quality and infection control are more important than ever. This quarter shows what we're capable of when innovation, execution, and purpose come together. We're just getting started. Thank you to our team, our customers, and our shareholders for being on this journey with us. With that, we'll now open the line for questions. Operator, please go ahead. Operator00:10:45We will now begin the question and answer session. To ask a question, you may press star then one on your telephone keypad. If you are using a speaker phone, please pick up your handset before pressing the keys. If at any time your question has been addressed and you would like to withdraw your questions, please press star then two. At this time, we will momentarily spin our roster. Our first question comes from Thomas McGovern with Mattson Group. Please go ahead. Speaker 100:11:23Thank you for taking my question. To wrap on the quarter, obviously, it's great to see some of those KPIs you discussed in the prepared remarks. Our retention rate, all-time high active customer sites. As noted, it seems to be reflective of several of these initiatives that you implemented, whether that's the installation and replacement program, the app, or the expanded sales force. I just want to understand where you're at with each of those initiatives. Where do you really foresee the bulk of this growth? Is it evenly divided amongst those, or is there one initiative in particular that you think really drove growth in the quarter? Maybe beyond that, just talk a little bit about how you see the continued rollout of this, particularly as it relates to the app and some of the innovations you guys have recently launched. Speaker 100:12:07Just give us an idea of the trajectories of the business moving throughout the rest of the year. Thanks. Speaker 300:12:14Hey, Bob, it's great to talk to you again. Good questions, really good questions. All of them make me think back to a year ago when I was looking at two quarters of not so high top-line performance. When we were marketing about things that we're doing to try to convert that back into more sustainable growth, one of the things we noted last year was that we weren't losing customers, but our customers were not reordering filters at the rates at which they were supposed to. That really is how the whole filter tracking app and some of the service initiatives were born. We saw that as how do we remind our customers not to just leave it in because it's still floating in the water, but actually do and follow the recommended procedures for how we implement. That’s where that came from. Speaker 300:13:01It was a combination of the app allowing us to have visibility to where each filter is being installed, the service capabilities allowing us to help the customer if they don't have the personnel, the time, or knowledge to be able to change out the filters unless they were first installed, and really having the sales team focus on helping continue to drive those very strong relationships. By being present and finding out if they're in trouble and really giving that customer a great experience, they realized that the filter was giving them peace of mind and also helping to protect from some of the things that are causing the negative headlines and bacteria and infections. A combination of those three. I think it started with the app because it just raised visibility, but the service implementation took the visibility and turned it into action. Speaker 300:13:54We created a model that is sustainable, and we can continue to capitalize on that growth because it doesn't do anything good if you close 600 customers, but then have existing customers not reorder as they're supposed to, especially in a time when the number of hospital beds has been flat over the past 5 to 10 years. That growth is deliberate, intentional, and I believe sustainable based on a lot of the SD askings that we've been talking about for the past few months here. Speaker 100:14:24That's good. I appreciate that response. Maybe a second question from me. Looking at your expanded sales force, you guys are obviously, as you've noticed, looking to expand your asset customer size. You mentioned in your prepared remarks that one of the big growth catalysts you see in the near term is pursuing additional verticals. I'm just curious, with that stance now, do you believe that you have efficient sales force to leverage both maintaining your current active customer size, keeping them happy, keeping kind of hands-on, as well as pursuing these growth avenues in verticals outside of healthcare? Do you expect to have to add additional sales force as you guys kind of continue to move along with your growth strategies? Speaker 300:15:06Another great question. You really actually hit on these only hindrances here right now for our growth. We don't have the sales force we need in every place location to grow. We've been pretty strategic about where we deploy resources, people, hands, and expertise. In the past, we've had to really focus on maybe areas where there is high population density or higher probability, whereas now we're able to go into areas and locations in the states and regions where there hasn't been much attention being paid. What we're finding is that a lot of these people just don't understand the importance of the pathological mitigation or biological remediation. It starts with education. Speaker 300:15:51We've been able to reach more of these different opportunities and potential customers through different speaking engagements, different posts on LinkedIn and other social media outlets, and really getting the name known so that we are using our existing staff to cover where we can, but also having to augment with junior associates and others who can come in and help take care of what we've got while these amazing experts go out and get new business. That undergathered approach model has really been quite effective. What we're noticing is that we're just going to have to keep expanding it. It's working very well. Speaker 100:16:28Good. I appreciate those responses. Very helpful as always. I can hand the call off to the next person here. Thank you. Operator00:16:39This concludes our question and answer session. The conference is now concluded. Thank you for attending today's presentation. You may now disconnect.Read morePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Nephros Earnings HeadlinesFinancial Comparison: Nephros (NASDAQ:NEPH) & InterCure (NASDAQ:INCR)May 18 at 3:37 AM | americanbankingnews.comUS$7.00 - That's What Analysts Think Nephros, Inc. (NASDAQ:NEPH) Is Worth After These ResultsMay 11, 2026 | finance.yahoo.comHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall of Fame Trader Jon Najarian now says EVERYONE is missing an even bigger story about the SpaceX IPO… That it's just the start of an Elon Musk $44 trillion "Superconvergence…" An event that could kick off as soon as June 9th.May 18 at 1:00 AM | Banyan Hill Publishing (Ad)Nephros (NEPH) Q1 2026 Earnings TranscriptMay 8, 2026 | fool.comNephros, Inc. Q1 2026 Earnings Call SummaryMay 8, 2026 | finance.yahoo.comNephros expects tariff relief from 10% rate to support margins later in 2026May 8, 2026 | seekingalpha.comSee More Nephros Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Nephros? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nephros and other key companies, straight to your email. Email Address About NephrosNephros (NASDAQ:NEPH), Inc. is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response. The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems. Nephros’ Water Purification System (WPS) is engineered to meet stringent U.S. Army and World Health Organization guidelines for field use, delivering potable water from untreated sources. In parallel, the MembraPure™ brand serves pharmaceutical and biotech customers requiring laboratory-grade water for research and manufacturing. Nephros holds FDA 510(k) clearance for its medical-grade hollow fiber filters, underpinning its role in critical patient care applications. The company distributes products directly to healthcare providers and partners with OEMs and authorized distributors to serve markets across North America and select international territories. Its technology has been adopted by hospitals seeking to safeguard dialysis water and by research institutions requiring ultrapure water for sensitive assays. Founded in 2005 and headquartered in Kinnelon, New Jersey, Nephros operates under the leadership of President and Chief Executive Officer Hal S. Zarem. The company maintains a focus on product innovation through ongoing research and development efforts, pursuing commercial partnerships and clinical collaborations to expand its footprint in water purification and filtration solutions.View Nephros ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why Applied Optoelectronics Stock May Be Near a Turning PointIs Everspin Technologies the Next AI Edge Breakout?Peloton Stock Gives Back Gains After Upbeat Earnings ReportDatavault Gains Traction: 5 Reasons to Sell NowTMC Stock: Why This Pre-Revenue Miner Is Worth WatchingRobinhood, SoFi, and Webull Are Telling Very Different StoriesViking Sails to All-Time Highs—Fundamentals Signal More to Come Upcoming Earnings Palo Alto Networks (5/19/2026)Home Depot (5/19/2026)Keysight Technologies (5/19/2026)Analog Devices (5/20/2026)Intuit (5/20/2026)NVIDIA (5/20/2026)Lowe's Companies (5/20/2026)Medtronic (5/20/2026)Target (5/20/2026)TJX Companies (5/20/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 4 speakers on the call. Operator00:00:00Okay, and welcome to the Nephros, Inc. second quarter 2025 financial results conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your questions, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to Karen Smith in PTG Advisory. Please go ahead. Speaker 200:00:36Thank you, Megan. Good afternoon, everyone. This is Karen Smith with PTG Advisory. Thank you all for participating in Nephros's second quarter 2025 conference call. Before we begin, I would like to caution that comments made during this conference call by management will contain forward-looking statements regarding the operations and future results of Nephros. On call here to review Nephros's bilingual statistics and exchange commission, including without limitation, the company is formed from 12, be 10 to identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements. Speaker 200:01:13Factors that may affect the company's results include, but are not limited to, Nephros's ability to successfully, timely, and cost-effectively market and sell its products and service offerings, the rate of adoption of its products and services by hospitals and other healthcare providers, the success of its commercialization efforts, and the effect of existing and new regulatory requirements on Nephros's business and other economic and competitive factors. The contents of this conference call contain time-sensitive information. It is accurate only as of the date of the live call today, August 7, 2025. I'm going to undertake no obligation to revise or update any statements to reflect events or circumstances as to the date of this conference call, except as required by law. I would now like to turn the call over to Nephros's President and Chief Executive Officer, Robert Banks. Robert, please go ahead. Speaker 300:02:05Thank you, Karen. Good afternoon, everyone. I'm thrilled to be speaking with you today as we share our Q2 2025 results. We've grown our total 12-month revenue from $13.8 million to $16.7 million, added more than 400 new active customer sites over the past two years, and most importantly, have continued to prove our strategy works. Q2 was another high-achieving quarter. Net revenue reached $4.4 million, up 36% over Q2 last year, and marks the third consecutive quarter of profitability. These are not just financial milestones, they are clear signals of durable momentum and strong operational execution. When you zoom out to look at the first half of 2025, the growth becomes even more compelling. The first half of 2025 revenue hit $9.3 million, a 37% increase over the same period in 2024. Every region outperformed its first half targets. Speaker 300:03:16Overall, we delivered well above our internal targets, reinforcing both the resilience and scalability of our business. Much of this success is driven by our core programmatic business, which has now seen 40% compound growth over the past two years. In fact, programmatic sales reached all-time highs, confirming the efficacy of our recurring revenue model. We have also seen encouraging traction in other key areas: a thriving installation program, which has accelerated reorder rates and expanded our footprint, a record level of programmatic sales, even with lower emergency response volumes, the strategic expansion of our sales teams into non-healthcare verticals has begun to pay off, and growing customer adoption of our filter tracking app, which has improved visibility, compliance, and support, with thousands of filters now being tracked. This quarter's strong execution reflects the entire team's commitment, from sales and operations to product and customer success. Speaker 300:04:29We now serve over 1,500 active customer sites and are delighted that our Q2 brought in the highest retention rate of the past six quarters. Looking ahead, we are focused on three things: expanding into underserved verticals like dental, government, and municipal facilities, bringing new innovations to market like our S100 microfilter and 20-inch HydraGuard, which have unlocked opportunities across sterile processing, laboratories, and beyond, and lastly, executing with operational discipline while continuing to protect profitability. To everyone who has supported our journey so far, thank you. I am deeply proud of what we've built and even more excited about what's next. With that, I'll turn the call over to our CFO, Judy Krandel, for a more detailed look at our financials. Judy? Operator00:05:32Thanks, Robert. I will now provide a closer look at Nephros's financial performance in the second quarter and first half of 2025. We reported second quarter net revenue of $4.4 million, a 36% increase over the corresponding period in 2024, reflecting strong growth in our programmatic business and emergency response business. Active customer sites continued to grow and were over 1,600 as of June 30, 2025, slightly higher than at March 31, 2025. Gross margins in the quarter also increased to 63% compared with 59% in Q2 2024, an improvement of 4 percentage points. The improvement in gross margins in 2025 was primarily driven by a reduction in shipping costs and inventory reserves adjustment. Research and development expenses in the quarter were $311,000 compared to $254,000 for the same quarter in 2024. R&D expenses were higher this year due to an increase in headcount. Operator00:06:41Sales, general, and administrative expenses in the quarter were $2.2 million compared to $1.9 million for the corresponding period in 2024, an increase of 13% due to higher sales commissions resulting from our increased revenue, higher pool of employee bonuses, and higher stock compensation expense. We are very pleased to report positive net income for the quarter of $237,000 compared to a net loss of $289,000 in the same period last year. Adjusted EBITDA in the quarter was positive $355,000 compared to a loss of $133,000 during the same period in 2024. Net cash provided by operating activities was $994,000 in the second quarter of 2025 versus net cash used of $501,000 in the prior year period, an improvement of $1,495,000. Net cash provided in the second quarter reflects primarily our positive net income, a decrease in accounts receivable, and an increase in accrued expenses. Operator00:07:55Net cash used in the second quarter of 2024 reflects primarily the net loss in that period and an increase in accounts receivable and inventory. Moving on to the six months, the first half of this year, sales for the six months ending June 30, 2025 increased by 37% to $9.2 million from the prior year period, reflecting strong growth in our programmatic business and emergency response business. Gross margins improved to 64% in the first half of 2025 from 61% in the prior year period. The increase in gross margins was primarily driven by lower product costs resulting from a more favorable product mix and a reduction in inventory reserve adjustment. SG&A expenses increased by 9% in the first half of 2025 versus the prior year period due to higher sales commission expense, increased bonus accrual, and higher stock-based compensation expense. Operator00:09:00Net income increased to $795,000 in the first half of 2025 from a net loss of $458,000 in the prior year period. Adjusted EBITDA in the first half of the year was positive $1,022,000 compared to a loss of $228,000 during the same period in 2024. Our cash balance on June 30, 2025 was $5.1 million compared to $3.8 million as of December 31, 2024, and we continued to be debt-free. Please refer to today's press release for more details about the calculation of adjusted EBITDA and its reconciliation to GAAP net income or loss. Additional information about our results can be found in our filing in Form 10-Q, which we also filed this afternoon. I will now turn the call back to Robert for some closing remarks. Robert, please go ahead. Speaker 300:10:02Thank you, Judy. With an eye towards the future, we remain focused on scaling our successes and exploring new ways to drive value. The strides we've made operationally, commercially, and financially position Nephros to lead in a future where water quality and infection control are more important than ever. This quarter shows what we're capable of when innovation, execution, and purpose come together. We're just getting started. Thank you to our team, our customers, and our shareholders for being on this journey with us. With that, we'll now open the line for questions. Operator, please go ahead. Operator00:10:45We will now begin the question and answer session. To ask a question, you may press star then one on your telephone keypad. If you are using a speaker phone, please pick up your handset before pressing the keys. If at any time your question has been addressed and you would like to withdraw your questions, please press star then two. At this time, we will momentarily spin our roster. Our first question comes from Thomas McGovern with Mattson Group. Please go ahead. Speaker 100:11:23Thank you for taking my question. To wrap on the quarter, obviously, it's great to see some of those KPIs you discussed in the prepared remarks. Our retention rate, all-time high active customer sites. As noted, it seems to be reflective of several of these initiatives that you implemented, whether that's the installation and replacement program, the app, or the expanded sales force. I just want to understand where you're at with each of those initiatives. Where do you really foresee the bulk of this growth? Is it evenly divided amongst those, or is there one initiative in particular that you think really drove growth in the quarter? Maybe beyond that, just talk a little bit about how you see the continued rollout of this, particularly as it relates to the app and some of the innovations you guys have recently launched. Speaker 100:12:07Just give us an idea of the trajectories of the business moving throughout the rest of the year. Thanks. Speaker 300:12:14Hey, Bob, it's great to talk to you again. Good questions, really good questions. All of them make me think back to a year ago when I was looking at two quarters of not so high top-line performance. When we were marketing about things that we're doing to try to convert that back into more sustainable growth, one of the things we noted last year was that we weren't losing customers, but our customers were not reordering filters at the rates at which they were supposed to. That really is how the whole filter tracking app and some of the service initiatives were born. We saw that as how do we remind our customers not to just leave it in because it's still floating in the water, but actually do and follow the recommended procedures for how we implement. That’s where that came from. Speaker 300:13:01It was a combination of the app allowing us to have visibility to where each filter is being installed, the service capabilities allowing us to help the customer if they don't have the personnel, the time, or knowledge to be able to change out the filters unless they were first installed, and really having the sales team focus on helping continue to drive those very strong relationships. By being present and finding out if they're in trouble and really giving that customer a great experience, they realized that the filter was giving them peace of mind and also helping to protect from some of the things that are causing the negative headlines and bacteria and infections. A combination of those three. I think it started with the app because it just raised visibility, but the service implementation took the visibility and turned it into action. Speaker 300:13:54We created a model that is sustainable, and we can continue to capitalize on that growth because it doesn't do anything good if you close 600 customers, but then have existing customers not reorder as they're supposed to, especially in a time when the number of hospital beds has been flat over the past 5 to 10 years. That growth is deliberate, intentional, and I believe sustainable based on a lot of the SD askings that we've been talking about for the past few months here. Speaker 100:14:24That's good. I appreciate that response. Maybe a second question from me. Looking at your expanded sales force, you guys are obviously, as you've noticed, looking to expand your asset customer size. You mentioned in your prepared remarks that one of the big growth catalysts you see in the near term is pursuing additional verticals. I'm just curious, with that stance now, do you believe that you have efficient sales force to leverage both maintaining your current active customer size, keeping them happy, keeping kind of hands-on, as well as pursuing these growth avenues in verticals outside of healthcare? Do you expect to have to add additional sales force as you guys kind of continue to move along with your growth strategies? Speaker 300:15:06Another great question. You really actually hit on these only hindrances here right now for our growth. We don't have the sales force we need in every place location to grow. We've been pretty strategic about where we deploy resources, people, hands, and expertise. In the past, we've had to really focus on maybe areas where there is high population density or higher probability, whereas now we're able to go into areas and locations in the states and regions where there hasn't been much attention being paid. What we're finding is that a lot of these people just don't understand the importance of the pathological mitigation or biological remediation. It starts with education. Speaker 300:15:51We've been able to reach more of these different opportunities and potential customers through different speaking engagements, different posts on LinkedIn and other social media outlets, and really getting the name known so that we are using our existing staff to cover where we can, but also having to augment with junior associates and others who can come in and help take care of what we've got while these amazing experts go out and get new business. That undergathered approach model has really been quite effective. What we're noticing is that we're just going to have to keep expanding it. It's working very well. Speaker 100:16:28Good. I appreciate those responses. Very helpful as always. I can hand the call off to the next person here. Thank you. Operator00:16:39This concludes our question and answer session. The conference is now concluded. Thank you for attending today's presentation. You may now disconnect.Read morePowered by